Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2018 (2018), Article ID 2426712, 10 pages
https://doi.org/10.1155/2018/2426712
Review Article

Targeting Mitochondrial Bioenergetics as a Therapeutic Strategy for Chronic Lymphocytic Leukemia

1Research Institute in Oncology and Hematology, CancerCare Manitoba, Winnipeg, Canada
2Department of Biochemistry and Medical Genetics, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada
3Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada

Correspondence should be addressed to Versha Banerji; ac.bm.eracrecnac@1ijrenabv

Received 24 June 2017; Accepted 6 November 2017; Published 28 February 2018

Academic Editor: Peng Huang

Copyright © 2018 Subir Roy Chowdhury and Versha Banerji. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Hallek, B. D. Cheson, D. Catovsky et al., “Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines,” Blood, vol. 111, no. 12, pp. 5446–5456, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. T. D. Shanafelt, N. E. Kay, K. G. Rabe et al., “Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population,” Leukemia, vol. 26, no. 2, pp. 373–376, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. M. D. Seftel, A. A. Demers, V. Banerji et al., “High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: a population-based Canadian cohort,” Leukemia Research, vol. 33, no. 11, pp. 1463–1468, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Stilgenbauer, “Prognostic markers and standard management of chronic lymphocytic leukemia,” Hematology, vol. 2015, pp. 368–377, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. K. R. Rai and P. Jain, “Chronic lymphocytic leukemia (CLL)—then and now,” American Journal of Hematology, vol. 91, pp. 330–340, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Hallek, “Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment,” American Journal of Hematology, vol. 90, no. 5, pp. 446–460, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Wawrzyniak, A. Kotkowska, J. Z. Blonski et al., “Clonal evolution in CLL patients as detected by FISH versus chromosome banding analysis, and its clinical significance,” European Journal of Haematology, vol. 92, no. 2, pp. 91–101, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. N. E. Kay, E. A. Ranheim, and L. C. Peterson, “Tumor suppressor genes and clonal evolution in B-CLL,” Leukemia & Lymphoma, vol. 18, no. 1-2, pp. 41–49, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Cheong, C. Lu, T. Lindsten, and C. B. Thompson, “Therapeutic targets in cancer cell metabolism and autophagy,” Nature Biotechnology, vol. 30, no. 7, pp. 671–678, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Zhang, D. Trachootham, J. Liu et al., “Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia,” Nature Cell Biology, vol. 14, no. 3, pp. 276–286, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Lagneaux, A. Delforge, D. Bron, C. de Bruyn, and P. Stryckmans, “Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells,” Blood, vol. 91, no. 7, pp. 2387–2396, 1998. View at Google Scholar
  13. M. Grdisa, “Influence of CD40 ligation on survival and apoptosis of B-CLL cells in vitro,” Leukemia Research, vol. 27, no. 10, pp. 951–956, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. R. A. Cairns, I. S. Harris, and T. W. Mak, “Regulation of cancer cell metabolism,” Nature Reviews Cancer, vol. 11, no. 2, pp. 85–95, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Vandenabeele, L. Galluzzi, T. vanden Berghe, and G. Kroemer, “Molecular mechanisms of necroptosis: an ordered cellular explosion,” Nature Reviews Molecular Cell Biology, vol. 11, no. 10, pp. 700–714, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. D. A. Tennant, R. V. Duran, and E. Gottlieb, “Targeting metabolic transformation for cancer therapy,” Nature Reviews Cancer, vol. 10, no. 4, pp. 267–277, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Kroemer, “Mitochondria in cancer,” Oncogene, vol. 25, no. 34, pp. 4630–4632, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. W. X. Zong, J. D. Rabinowitz, and E. White, “Mitochondria and cancer,” Molecular Cell, vol. 61, no. 5, pp. 667–676, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. J. S. Carew, Y. Zhou, M. Albitar, J. D. Carew, M. J. Keating, and P. Huang, “Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications,” Leukemia, vol. 17, no. 8, pp. 1437–1447, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Anderson, A. T. Bankier, B. G. Barrell et al., “Sequence and organization of the human mitochondrial genome,” Nature, vol. 290, no. 5806, pp. 457–465, 1981. View at Publisher · View at Google Scholar · View at Scopus
  21. D. C. Wallace, “Mitochondrial diseases in man and mouse,” Science, vol. 283, no. 5407, pp. 1482–1488, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. S. E. Weinberg and N. S. Chandel, “Targeting mitochondria metabolism for cancer therapy,” Nature Chemical Biology, vol. 11, no. 1, pp. 9–15, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. P. L. Pedersen, “Mitochondrial events in the life and death of animal cells: a brief overview,” Journal of Bioenergetics and Biomembranes, vol. 31, no. 4, pp. 291–304, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. M. D. Brand and D. G. Nicholls, “Assessing mitochondrial dysfunction in cells,” The Biochemical Journal, vol. 435, no. 2, pp. 297–312, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. S. K. Roy Chowdhury, D. R. Smith, A. Saleh et al., “Impaired adenosine monophosphate-activated protein kinase signalling in dorsal root ganglia neurons is linked to mitochondrial dysfunction and peripheral neuropathy in diabetes,” Brain, vol. 135, no. 6, pp. 1751–1766, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. H. E. Speedy, M. C. di Bernardo, G. P. Sava et al., “A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia,” Nature Genetics, vol. 46, no. 1, pp. 56–60, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. S. I. Berndt, N. J. Camp, C. F. Skibola et al., “Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia,” Nature Communications, vol. 7, article 10933, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. F. S. Hosnijeh, Q. Lan, N. Rothman et al., “Mitochondrial DNA copy number and future risk of B-cell lymphoma in a nested case-control study in the prospective EPIC cohort,” Blood, vol. 124, no. 4, pp. 530–535, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Jitschin, A. D. Hofmann, H. Bruns et al., “Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia,” Blood, vol. 123, no. 17, pp. 2663–2672, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. J. B. Stewart and P. F. Chinnery, “The dynamics of mitochondrial DNA heteroplasmy: implications for human health and disease,” Nature Reviews Genetics, vol. 16, no. 9, pp. 530–542, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. J. F. Zhou, P. Chen, Y. H. Zhou, L. Zhang, and H. H. Chen, “3,4-Methylenedioxymethamphetamine (MDMA) abuse may cause oxidative stress and potential free radical damage,” Free Radical Research, vol. 37, no. 5, pp. 491–497, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Trachootham, J. Alexandre, and P. Huang, “Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?” Nature Reviews Drug Discovery, vol. 8, no. 7, pp. 579–591, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. B. D'Autreaux and M. B. Toledano, “ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis,” Nature Reviews Molecular Cell Biology, vol. 8, no. 10, pp. 813–824, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Takahashi, M. G. V. Hanson, H. R. Norell et al., “Preferential cell death of CD8+ effector memory (CCR7CD45RA) T cells by hydrogen peroxide-induced oxidative stress,” Journal of Immunology, vol. 174, no. 10, pp. 6080–6087, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. G. M. DeNicola, F. A. Karreth, T. J. Humpton et al., “Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis,” Nature, vol. 475, no. 7354, pp. 106–109, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Pervaiz and M. V. Clement, “Tumor intracellular redox status and drug resistance-serendipity or a causal relationship?” Current Pharmaceutical Design, vol. 10, no. 16, pp. 1969–1977, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. R. P. Wu, T. Hayashi, H. B. Cottam et al., “Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 16, pp. 7479–7484, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Fukuda, H. Zhang, J.w. Kim, L. Shimoda, C. V. Dang, and G. L. Semenza, “HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells,” Cell, vol. 129, no. 1, pp. 111–122, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. J. M. Funes, M. Quintero, S. Henderson et al., “Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 15, pp. 6223–6228, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Rodriguez-Enriquez, P. A. Vital-González, F. L. Flores-Rodríguez, A. Marín-Hernández, L. Ruiz-Azuara, and R. Moreno-Sánchez, “Control of cellular proliferation by modulation of oxidative phosphorylation in human and rodent fast-growing tumor cells,” Toxicology and Applied Pharmacology, vol. 215, no. 2, pp. 208–217, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. J. A. Burger, “Nurture versus nature: the microenvironment in chronic lymphocytic leukemia,” Hematology, vol. 2011, pp. 96–103, 2011. View at Publisher · View at Google Scholar
  42. P. P. Liu, J. Liu, W. Q. Jiang et al., “Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline,” Oncogene, vol. 35, no. 43, pp. 5663–5673, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Salimi, M. H. Roudkenar, L. Sadeghi et al., “Ellagic acid, a polyphenolic compound, selectively induces ROS-mediated apoptosis in cancerous B-lymphocytes of CLL patients by directly targeting mitochondria,” Redox Biology, vol. 6, pp. 461–471, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. N. P. Seeram, L. S. Adams, S. M. Henning et al., “In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice,” The Journal of Nutritional Biochemistry, vol. 16, no. 6, pp. 360–367, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. B. A. Narayanan, O. Geoffroy, M. C. Willingham, G. G. Re, and D. W. Nixon, “p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells,” Cancer Letters, vol. 136, no. 2, pp. 215–221, 1999. View at Publisher · View at Google Scholar · View at Scopus
  46. C. Agnoletto, E. Melloni, F. Casciano et al., “Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3,” Oncotarget, vol. 5, no. 12, pp. 4347–4360, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Salimi, M. H. Roudkenar, L. Sadeghi et al., “Selective anticancer activity of acacetin against chronic lymphocytic leukemia using both in vivo and in vitro methods: key role of oxidative stress and cancerous mitochondria,” Nutrition and Cancer, vol. 68, no. 8, pp. 1404–1416, 2016. View at Publisher · View at Google Scholar · View at Scopus
  48. B. Viollet, B. Guigas, N. S. Garcia, J. Leclerc, M. Foretz, and F. Andreelli, “Cellular and molecular mechanisms of metformin: an overview,” Clinical Science, vol. 122, no. 6, pp. 253–270, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. H. R. Bridges, A. J. Y. Jones, M. N. Pollak, and J. Hirst, “Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria,” The Biochemical Journal, vol. 462, no. 3, pp. 475–487, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Y. El-Mir, V. Nogueira, E. Fontaine, N. Avéret, M. Rigoulet, and X. Leverve, “Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I,” The Journal of Biological Chemistry, vol. 275, no. 1, pp. 223–228, 2000. View at Publisher · View at Google Scholar · View at Scopus
  51. G. Zhou, R. Myers, Y. Li et al., “Role of AMP-activated protein kinase in mechanism of metformin action,” The Journal of Clinical Investigation, vol. 108, no. 8, pp. 1167–1174, 2001. View at Publisher · View at Google Scholar
  52. B. N. Zordoky, D. Bark, C. L. Soltys, M. M. Sung, and J. R. Dyck, “The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention,” Biochimica et Biophysica Acta (BBA) - General Subjects, vol. 1840, no. 6, pp. 1943–1957, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. L. A. Cantrell, C. Zhou, A. Mendivil, K. M. Malloy, P. A. Gehrig, and V. L. Bae-Jump, “Metformin is a potent inhibitor of endometrial cancer cell proliferation—implications for a novel treatment strategy,” Gynecologic Oncology, vol. 116, no. 1, pp. 92–98, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Bruno, B. Ledda, C. Tenca et al., “Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells,” Oncotarget, vol. 6, no. 26, pp. 22624–22640, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. Y. Zhou, E. O. Hileman, W. Plunkett, M. J. Keating, and P. Huang, “Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents,” Blood, vol. 101, no. 10, pp. 4098–4104, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Trachootham, H. Zhang, W. Zhang et al., “Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism,” Blood, vol. 112, no. 5, pp. 1912–1922, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. I. Gehrke, E. D. J. Bouchard, S. Beiggi et al., “On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells,” Clinical Cancer Research, vol. 20, no. 18, pp. 4861–4872, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Cagnetta, I. Caffa, C. Acharya et al., “APO866 increases antitumor activity of cyclosporin-a by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells,” Clinical Cancer Research, vol. 21, no. 17, pp. 3934–3945, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Y. Yoon, G. Ishdorj, B. A. Graham, J. B. Johnston, and S. B. Gibson, “Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells,” Apoptosis, vol. 19, no. 1, pp. 191–200, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. V. A. Pullarkat and E. M. Newman, “BCL2 inhibition by venetoclax: targeting the Achilles’ heel of the acute myeloid leukemia stem cell?” Cancer Discovery, vol. 6, no. 10, pp. 1082-1083, 2016. View at Publisher · View at Google Scholar · View at Scopus
  61. S. K. Tahir, M. L. Smith, P. Hessler et al., “Potential mechanisms of resistance to venetoclax and strategies to circumvent it,” BMC Cancer, vol. 17, no. 1, p. 399, 2017. View at Publisher · View at Google Scholar · View at Scopus
  62. M. A. Anderson, J. Deng, J. F. Seymour et al., “The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism,” Blood, vol. 127, no. 25, pp. 3215–3224, 2016. View at Publisher · View at Google Scholar · View at Scopus
  63. A. W. Roberts, M. S. Davids, J. M. Pagel et al., “Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia,” The New England Journal of Medicine, vol. 374, no. 4, pp. 311–322, 2016. View at Publisher · View at Google Scholar · View at Scopus
  64. G. W. Rao and W. X. Hu, “Synthesis, structure analysis, and antitumor activity of 3,6-disubstituted-1,4-dihydro-1,2,4,5-tetrazine derivatives,” Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 14, pp. 3702–3705, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. L. N. Qiu, Y. L. Zhou, Z. N. Wang, Q. Huang, and W. X. Hu, “ZGDHu-1 promotes apoptosis of chronic lymphocytic leukemia cells,” International Journal of Oncology, vol. 41, no. 2, pp. 533–540, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Qiu, J. Liu, Z. Wang, W. Hu, Q. Huang, and Y. Zhou, “ZGDHu-1 and fludarabine have a synergistic effect on apoptosis of chronic lymphocytic leukemia cells,” Oncology Reports, vol. 34, no. 3, pp. 1239–1248, 2015. View at Publisher · View at Google Scholar · View at Scopus
  67. C. Prinz, E. Vasyutina, G. Lohmann et al., “Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden,” Molecular Cancer, vol. 14, no. 1, p. 114, 2015. View at Publisher · View at Google Scholar · View at Scopus
  68. A. J. Johnson, D. M. Lucas, N. Muthusamy et al., “Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia,” Blood, vol. 108, no. 4, pp. 1334–1338, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. W. Chen, K. Balakrishnan, Y. Kuang et al., “Reactive oxygen species (ROS) inducible DNA cross-linking agents and their effect on cancer cells and normal lymphocytes,” Journal of Medicinal Chemistry, vol. 57, no. 11, pp. 4498–4510, 2014. View at Publisher · View at Google Scholar · View at Scopus